MindBio Therapeutics Corp. (CSE:MBIO)

Canada flag Canada · Delayed Price · Currency is CAD
0.0050
-0.0050 (-50.00%)
Jul 18, 2025, 4:00 PM EDT
-85.71%
Market Cap3.12M
Revenue (ttm)-565.34K
Net Income (ttm)-1.46M
Shares Out623.30M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume13,000
Average Volume205,230
Open0.0050
Previous Close0.0100
Day's Range0.0050 - 0.0050
52-Week Range0.0050 - 0.0400
Beta0.16
RSI43.90
Earnings DateOct 29, 2025

About MindBio Therapeutics

MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Australasia. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, chronic pain, cognitive impairment, post-traumatic stress disorder, panic disorder, and opiate addictions. It also establishes and executes research protocols through formal clinical trials that are facilitated v... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol MBIO
Full Company Profile

Financial Performance

Financial numbers in AUD Financial Statements

News

There is no news available yet.